Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axalta Coating Systems Ltd.AXTA · Entity 3667 | SVP & CHRO | August 09, 2023 | August 11, 2023 |
| FMC CORPFMC · Entity 4704 | Executive VP & Chief HRO | September 28, 2026 | September 30, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | SVP, Global Human Resources | June 07, 2021 | June 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axalta Coating Systems Ltd.
Report date August 09, 2023 · Filed August 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 4,001 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Sale · Disposed 17,008 · Balance 4,001 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
FMC CORP
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,558 |
Reported balance
After 2026-09-28 transaction · row 1
1 source rowRow 1 · 2026-09-28 · Tax withholding · Disposed 5,137 · Balance 63,558 |
HAEMONETICS CORP
Report date June 07, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,216 |
Reported balance
After 2021-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-07 · Sale · Disposed 195 · Balance 4,216 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: This number includes unvested RSUs previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 30, 2026 20:19 UTC | FMC CORP FMC · Entity 4704 | Tax withholdingCommon Stock | 5,137 | $9.58 | $49,212.46 |
DisclosureSEC source: 0000037785-26-000146 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,558 Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 00:50 UTC | FMC CORP FMC · Entity 4704 | Tax withholdingCommon Stock | 1,404 | $14.62 | $20,526.48 |
DisclosureSEC source: 0000950103-26-002678 · dp242146_4-scanlan.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,695 Read SEC document |
| February 19, 2026 Filed Feb 24, 2026 01:30 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 42,232 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-26-002511 · dp241974_4-scanlan.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,099 Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 17:09 UTC | FMC CORP FMC · Entity 4704 | Tax withholdingCommon Stock | 5,177 | $33.64 | $174,154.28 |
DisclosureSEC source: 0000037785-25-000088 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,867 Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 17:09 UTC | FMC CORP FMC · Entity 4704 | SaleCommon Stock | 3,790 | $34.00 | $128,860.00 |
DisclosureSEC source: 0000037785-25-000088 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,044 F1 · ownership.direct: The reported sale of 3,790 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 18:21 UTC | FMC CORP FMC · Entity 4704 | SaleCommon Stock | 1,510 | $37.49 | $56,609.90 |
DisclosureSEC source: 0000037785-25-000085 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,834 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 17:55 UTC | FMC CORP FMC · Entity 4704 | GrantStock Option (Right to Buy) · Derivative | 44,808 | $0.00 Strike: $38.25 | $0.00 |
DisclosureSEC source: 0001127602-25-006516 · form4.xml · derivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,808 Underlying: Common Stock · 44,808 shares Expires 2035-02-21 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 17:55 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 9,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006516 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,344 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 01:25 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 28 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006105 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,260 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 01:25 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006105 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,232 Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 18:47 UTC | FMC CORP FMC · Entity 4704 | SaleCommon Stock | 4,529 | $59.67 | $270,245.43 |
DisclosureSEC source: 0001127602-24-027176 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,649 Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 12:34 UTC | FMC CORP FMC · Entity 4704 | Tax withholdingCommon Stock | 5,132 | $65.97 | $338,558.04 |
DisclosureSEC source: 0001127602-24-024581 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,178 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 20:19 UTC | FMC CORP FMC · Entity 4704 | GrantStock Option (Right to Buy) · Derivative | 19,167 | $50.99 Strike: $50.99 | $977,325.33 |
DisclosureSEC source: 0001127602-24-006254 · form4.xml · derivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,167 Underlying: Common Stock · 19,167 shares Expires 2034-02-20 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 20:19 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 4,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006254 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,310 Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 14:29 UTC | FMC CORP FMC · Entity 4704 | GrantCommon Stock | 33,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-024846 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · Executive VP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,511 F1 · shares: Represents a grant of 33,511 restricted stock units ("RSUs"). The RSUs vest in three annual installments on the first, second, and third anniversaries of the grant date contingent on the reporting person's continued service on each applicable vesting date, subject to accelerated vesting under certain circumstances. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:30 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | SaleCommon Shares | 17,008 | $29.48 | $501,395.84 |
DisclosureSEC source: 0001209191-23-045443 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,001 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.47 to $29.51. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:51 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionRestricted Stock Units · Derivative | 16,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043717 · doc4.xml · derivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,267 Underlying: Common Shares · 16,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis. F3 · derivative.exercise_date: On July 27, 2022, the reporting person was granted 32,533 restricted stock units, vesting in two equal annual installments on the first and second anniversaries of the grant date. F3 · derivative.expiration_date: On July 27, 2022, the reporting person was granted 32,533 restricted stock units, vesting in two equal annual installments on the first and second anniversaries of the grant date. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:51 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Tax withholdingCommon Shares | 6,910 | $32.03 | $221,327.30 |
DisclosureSEC source: 0001209191-23-043717 · doc4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,009 F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:51 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionCommon Shares | 16,266 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043717 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common shares on a one-for-one basis. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionRestricted Stock Units · Derivative | 11,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · derivative · entry 6 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,545 Underlying: Common Shares · 11,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis. F4 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 23,090 restricted stock units, vesting 50% on each of the second and third anniversaries of the grant date. F4 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 23,090 restricted stock units, vesting 50% on each of the second and third anniversaries of the grant date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionRestricted Stock Units · Derivative | 2,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · derivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,874 Underlying: Common Shares · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis. F3 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022. F3 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Tax withholdingCommon Shares | 4,905 | $32.50 | $159,412.50 |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,653 F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionCommon Shares | 11,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common shares on a one-for-one basis. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Tax withholdingCommon Shares | 1,221 | $32.50 | $39,682.50 |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,013 F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:05 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionCommon Shares | 2,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-037971 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common shares on a one-for-one basis. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 01:23 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | GrantRestricted Stock Units · Derivative | 10,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015028 · doc4.xml · derivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,739 Underlying: Common Shares · 10,739 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd. F2 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:39 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionRestricted Stock Units · Derivative | 3,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010829 · doc4.xml · derivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,478 Underlying: Common Shares · 3,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis. F3 · derivative.exercise_date: On February 15, 2022, the reporting person was granted 9,716 restricted stock units, vesting in three equal annual installments beginning on February 15, 2023. F3 · derivative.expiration_date: On February 15, 2022, the reporting person was granted 9,716 restricted stock units, vesting in three equal annual installments beginning on February 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:39 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Tax withholdingCommon Shares | 1,529 | $29.55 | $45,181.95 |
DisclosureSEC source: 0001209191-23-010829 · doc4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361 F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:39 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionCommon Shares | 3,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-010829 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common shares on a one-for-one basis. Read SEC document |
| July 27, 2022 Filed Jul 27, 2022 22:59 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | GrantRestricted Stock Units · Derivative | 32,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043310 · doc4.xml · derivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,533 Underlying: Common Shares · 32,533 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd. F2 · derivative.exercise_date: This restricted stock unit grant vests in two equal annual installments on the first and second anniversaries of the grant date. F2 · derivative.expiration_date: This restricted stock unit grant vests in two equal annual installments on the first and second anniversaries of the grant date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:34 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionRestricted Stock Units · Derivative | 2,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037534 · doc4.xml · derivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,747 Underlying: Common Shares · 2,873 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common shares on a one-for-one basis. F3 · derivative.exercise_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022. F3 · derivative.expiration_date: On June 14, 2021, the reporting person was granted 8,620 restricted stock units, vesting in three equal annual installments beginning on June 14, 2022. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:34 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Tax withholdingCommon Shares | 1,221 | $24.20 | $29,548.20 |
DisclosureSEC source: 0001209191-22-037534 · doc4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,652 F2 · shares: Shares withheld to satisfy the tax withholding obligation applicable to the vesting of a portion of a restricted stock unit award. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:34 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | Exercise / conversionCommon Shares | 2,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037534 · doc4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common shares on a one-for-one basis. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:00 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | GrantRestricted Stock Units · Derivative | 9,716 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-011020 · doc4.xml · derivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,716 Underlying: Common Shares · 9,716 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd. F2 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:39 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | GrantRestricted Stock Units · Derivative | 8,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041020 · doc4.xml · derivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 Underlying: Common Shares · 8,620 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd. F3 · derivative.exercise_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: This restricted stock unit grant vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:39 UTC | Axalta Coating Systems Ltd. AXTA · Entity 3667 | GrantRestricted Stock Units · Derivative | 23,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041020 · doc4.xml · derivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP & CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,090 Underlying: Common Shares · 23,090 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of Axalta Coating Systems Ltd. F2 · derivative.exercise_date: This restricted stock unit grant vests 50% on each of the second and third anniversaries of the grant date. F2 · derivative.expiration_date: This restricted stock unit grant vests 50% on each of the second and third anniversaries of the grant date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 195 | $55.09 | $10,742.55 |
DisclosureSEC source: 0001127602-21-019526 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,216 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 21, 2021 10:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 112 | $55.19 | $6,181.28 |
DisclosureSEC source: 0001127602-21-017698 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2021 Filed May 18, 2021 22:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 102 | $55.97 | $5,708.94 |
DisclosureSEC source: 0001127602-21-017269 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,523 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 107 | $120.07 | $12,847.49 |
DisclosureSEC source: 0001127602-21-010074 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,380 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 6,869 | $91.53 | $628,719.57 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 6 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,487 F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,889 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · derivative · entry 7 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890 Underlying: Common Stock · 2,889 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,005 | $90.00 | $360,450.00 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 5 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,356 F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,889 | $41.64 | $120,297.96 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 4 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,417 | $87.71 | $387,415.07 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 111 | $89.29 | $9,911.19 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,889 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:53 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 11,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019788 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · kind: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:59 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 324 | $97.03 | $31,437.72 |
DisclosureSEC source: 0001127602-20-019381 · form4.xml · nonDerivative · entry 1 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 5,319 | $0.00 Strike: $103.37 | $0.00 |
DisclosureSEC source: 0001127602-20-017266 · form4.xml · derivative · entry 3 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,319 Underlying: Common Stock · 5,319 shares Expires 2027-05-18 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2020 Filed May 19, 2020 21:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-017266 · form4.xml · nonDerivative · entry 2 Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,038 F3 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs and 193 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.